Results 111 to 120 of about 226,969 (309)
European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender
BJS (British Journal of Surgery), EarlyView., 2020 Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.T. T. Seppälä, A. Latchford, I. Negoi, A. Sampaio Soares, R. Jimenez‐Rodriguez, L. Sánchez‐Guillén, D. G. Evans, N. Ryan, E. J. Crosbie, M. Dominguez‐Valentin, J. Burn, M. Kloor, M. von Knebel Doeberitz, F. J. B. van Duijnhoven, P. Quirke, J. R. Sampson, P. Møller, G. Möslein, on behalf of the European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP) +18 morewiley +1 more sourceDosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.Nicholas J. Campion, Dioni‐Pinelopi Petsiou, Florian C. Fally, Karina Berbalk, Noah F. Melamed, Aldine Tu, Christina Morgenstern, Fana Alem Kidane, Mohammed Zghaebi, Linda Liu, Minghao Pan, Tina J. Bartosik, Victoria Stanek, Katarina Gangl, Julia Eckl‐Dorna, Sven Schneider +15 morewiley +1 more sourceA retrospective observational analysis of post-pandemic influenza-related outcomes in the United Kingdom, 2010–2014
Human Vaccines & Immunotherapeutics, 2018 This study set out to evaluate influenza- and respiratory-related illnesses recorded during primary care physician consultations in England following the H1N1 pandemic in 2009 and to enable the development of a dynamic disease model.Sankarasubramanian Rajaram, Witold Wiecek, Richard Lawson, Betina Blak, Yanli Zhao, Judith Hackett, Robert Brody, Tehseen Salimi, Billy Amzal, Vishal Patel +9 moredoaj +1 more sourceExtent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background
A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.Nicholas J. Campion, Peta‐Lee Sacks, Lu Hui Png, Ruoxin Hua, Rhea Darbari Kaul, Raquel Alvarado, Christine Choy, Raymond Sacks, Peter Earls, Raewyn G. Campbell, Larry Kalish, Richard J. Harvey +11 morewiley +1 more sourceSUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]
, 2019 BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun +19 morecore +1 more sourceThe ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Nature CommunicationsThe Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy.Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry +55 moredoaj +1 more sourceRecurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up
American Journal of Hematology, EarlyView.Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids +16 morewiley +1 more sourceGeminale Difunktionalisierung von Ketonen durch C–S Bindungs‐insertion photogenerierter Donor–Donor Diazoverbindungen
Angewandte Chemie, EarlyView.Die geminale Difunktionalisierung leicht verfügbarer Bausteine ermöglicht einen schnellen Zugang zu molekularer Komplexität. Diese Arbeit stellt eine Strategie vor, um zwei unterschiedliche funktionelle Gruppen an einem Carbonylkohlenstoff zu installieren, indem dieser in eine Donor–Donor‐Diazo‐Verbindung überführt wird. Die Methode ist sowohl im Batch‐Vincent George, Aryaman Pattanaik, Daniel Maddox, Lukas M. Sigmund, Giovanna Mejia, Sara Pahlén, Simon O. Angerer, Maria Schmoll, Lisa Marie Schneider, Nidhal Selmi, Mikhail Kabeshov, Giulia Bergonzini, Julia Rehbein, Burkhard König +13 morewiley +1 more sourceMetabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
Communications BiologyTargeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROTAC) degrader ...Thomas G. Hayhow, Beth Williamson, Mandy Lawson, Natalie Cureton, Erin L. Braybrooke, Andrew Campbell, Rodrigo J. Carbajo, Azadeh Cheraghchi-Bashi, Elisabetta Chiarparin, Coura R. Diène, Charlene Fallan, David I. Fisher, Frederick W. Goldberg, Lorna Hopcroft, Philip Hopcroft, Anne Jackson, Jason G. Kettle, Teresa Klinowska, Ulrike Künzel, Gillian Lamont, Hilary J. Lewis, Gareth Maglennon, Scott Martin, Pablo Morentin Gutierrez, Christopher J. Morrow, Myria Nikolaou, J. Willem M. Nissink, Patrick O’Shea, Radoslaw Polanski, Markus Schade, James S. Scott, Aaron Smith, Judith Weber, Joanne Wilson, Bin Yang, Claire Crafter +35 moredoaj +1 more source
